Labeling Update Claims Survive Dismissal In Fosamax MDL

Law360, New York (August 15, 2013, 8:44 PM EDT) -- A New York federal judge ruled Thursday that manufacturers of generic versions of the bone drug Fosamax can be held liable for failing to match their warning labels to the brand-name label, in multidistrict litigation over a jaw condition allegedly caused by the drug.

U.S. District Judge John Keenan granted much of a dismissal motion filed by a group of generic Fosamax makers in hundreds of lawsuits over the drug, finding that the plaintiffs' design defect claims and a portion of their failure-to-warn claims are preempted...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.